Alpha Teknova, Inc.

NASDAQ:TKNO

Drug Manufacturers - Specialty & Generic

Healthcare
$7.88 +4.55%

+$0.23 today

Market cap
$495.68M
Beta
0.63
P/E (TTM)
-16.2
EPS (TTM)
-$0.32
52W Low $1.91High $6.68

Volume 0.30M

Average 0.13M

TKNO Net Income

Bottom-line profit after all expenses, interest, and taxes.

Alpha Teknova, Inc.NASDAQ: TKNO

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -$4.56M, compared with -$4.65M a year earlier. Trailing-twelve-month net income was -$17.17M.

Context

  • Net income amounted to 42.6% of revenue in FY2025, down 28.3 pp from a year earlier.
  • Net income grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 6 analysts of -$14.47M (+16.2%) for the fiscal year ending Dec 2026, a slowdown from the +35.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$4.56M+4.3% QoQ
Last fiscal yearDec 2025
-$17.26M+35.5% YoY
LTMMar 2026
-$17.17M+26.3% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.9%-26.8%-28.7 pp
1 year+35.5%+16.2%-19.3 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(17.26M) USD
Year-over-year change
+35.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How TKNO compares with its peers on the latest reported figures

  • TKNO's LTM Mar 2026 net income of -$17.17M is the 5th highest of the 8 companies compared; the peer median is -$10.5M.
  • Its year-over-year change of +26.3% is the 6th highest of 8, against a peer median of +60.3%.
  • Net income amounts to 41.1% of revenue for TKNO, versus a peer median of 14.0%.
TKNO Competitors Peer median
Net Income for TKNO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TECHBio-Techne CorporationLTM Sep 2026$171.97M +120.5%-13.9%14.0%
RGENRepligen CorporationLTM Jun 2026$41.54M +400.4%-35.9%5.3%
MLABMesa Laboratories, Inc.LTM Mar 2026$6.71M +440.0%+93.3%2.7%
BLFSBioLife Solutions, Inc.LTM Mar 2026-$10.5M -0.8%—10.5%
TKNOAlpha Teknova, Inc.LTM Mar 2026-$17.17M +26.3%—41.1%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026-$77.39M +60.3%—37.1%
LABStandard BioTools Inc.LTM Mar 2026-$94.08M +29.1%—109.1%
AZTAAzenta, Inc.LTM Sep 2026-$166.99M -212.8%—26.9%
Peer median (excluding TKNO) -$10.5M+60.3%-13.9%14.0%

Competitors are the stored peer set for TKNO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue36.89M41.42M36.68M37.75M40.52M
Cost of Revenue19.27M23.94M26.39M30.51M27.08M
Gross Profit17.62M17.48M10.3M7.23M13.44M
Gross Margin47.8%42.2%28.1%19.2%33.2%
Research & Development4.31M7.74M5.57M2.76M2.2M
Selling, General & Admin24.17M37.45M34.78M29.47M27.07M
Operating Expenses29.63M67.14M45.86M33.38M30.42M
Depreciation & Amortization2.88M3.17M5.66M6.58M6.34M
EBITDA(9.17M)(25.69M)(25.54M)(19.57M)(10.15M)
EBITDA Margin-24.8%-62.0%-69.6%-51.8%-25.0%
Operating Income(12.01M)(49.66M)(35.56M)(26.15M)(16.98M)
Operating Margin-32.5%-119.9%-96.9%-69.3%-41.9%
Interest Income0213K000
Interest Expense589K0833K687K710K
Other Income / Expenses(629K)268K(1.52M)(687K)(225K)
Income Before Tax(12.64M)(49.39M)(37.08M)(26.83M)(17.2M)
Pre-Tax Margin-34.3%-119.2%-101.1%-71.1%-42.5%
Income Tax Expense(2.83M)(1.92M)(298K)(88K)58K
Net Income(9.8M)(47.47M)(36.78M)(26.75M)(17.26M)
Net Margin-26.6%-114.6%-100.3%-70.9%-42.6%
EPS (Basic)(0.35)(1.69)(1.16)(0.57)(0.32)
EPS (Diluted)(0.35)(1.69)(1.16)(0.57)(0.32)
Weighted Avg Shares28.01M28.08M31.82M46.75M53.48M
Weighted Avg Shares (Diluted)28.01M28.08M31.82M46.75M53.48M

Alpha Teknova, Inc.

NASDAQ:TKNO

Intrinsic Alpha fair value

Locked

Current Price

$7.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.